| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Erratum to "A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis". Molecular therapy : the journal of the American Society of Gene Therapy. vol 23. issue 11. 2016-03-03. PMID:26606663. |
erratum to "a her2-specific modified fc fragment (fcab) induces antitumor effects through degradation of her2 and apoptosis". |
2016-03-03 |
2023-08-13 |
Not clear |
| Masaki Shiota, Jennifer L Bishop, Ario Takeuchi, Ka Mun Nip, Thomas Cordonnier, Eliana Beraldi, Hidetoshi Kuruma, Martin E Gleave, Amina Zoubeid. Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer. Oncotarget. vol 6. issue 11. 2016-03-01. PMID:25871401. |
her2 dependent ar activation in lncap and enzr cells was effectively blocked by treatment with the egfr/her2 inhibitor lapatinib, which reduced cell viability and increased apoptosis. |
2016-03-01 |
2023-08-13 |
Not clear |
| Kuo Jiang, Jia Li, Jipeng Yin, Qiong Ma, Bo Yan, Xiang Zhang, Lei Wang, Lifeng Wang, Tao Liu, Yinglong Zhang, Qingyu Fan, Angang Yang, Xiuchun Qiu, Baoan M. Targeted delivery of CXCR4-siRNA by scFv for HER2(+) breast cancer therapy. Biomaterials. vol 59. 2016-02-26. PMID:25956853. |
the e23sfv-9r binding sirna is able to specifically deliver the sirna to her2(+) breast cancer cells and concentrate and persist in orthotopic her2(+) breast cancer xenografts for at least 36 h. cxcr4si delivered by e23sfv-9r inhibited cxcr4 gene expression, reduced proliferation and metastasis and induced apoptosis in the her2(+) breast cancer bt-474 cell line in vitro. |
2016-02-26 |
2023-08-13 |
mouse |
| Elisa Pierpaoli, Elisa Damiani, Fiorenza Orlando, Guendalina Lucarini, Beatrice Bartozzi, Paolo Lombardi, Carmela Salvatore, Cristina Geroni, Abele Donati, Mauro Provincial. Antiangiogenic and antitumor activities of berberine derivative NAX014 compound in a transgenic murine model of HER2/neu-positive mammary carcinoma. Carcinogenesis. vol 36. issue 10. 2016-01-04. PMID:26168818. |
we recently demonstrated that bbr and its synthetic derivative 13-(4-chlorophenylethyl)berberine iodide, nax014, exert antiproliferative activity against her2-overexpressing breast cancer cells, inducing apoptosis, modulating the expression of cell cycle checkpoint molecules involved in cell senescence, and reducing both her2 expression and phosphorylation on tumor cells. |
2016-01-04 |
2023-08-13 |
mouse |
| Tsai-Yueh Luo, Po-Ching Cheng, Ping-Fang Chiang, Ting-Wu Chuang, Chung-Hsin Yeh, Wuu-Jyh Li. 188Re-HYNIC-trastuzumab enhances the effect of apoptosis induced by trastuzumab in HER2-overexpressing breast cancer cells. Annals of nuclear medicine. vol 29. issue 1. 2015-09-21. PMID:25238789. |
here, we try to examine the efficacy of cytotoxicity and apoptosis induction for (188)re-hynic-trastuzumab in cancer cell lines with various levels of her2. |
2015-09-21 |
2023-08-13 |
Not clear |
| Julie K Mason, Minghua Fu, Jianmin Chen, Lilian U Thompso. Flaxseed oil enhances the effectiveness of trastuzumab in reducing the growth of HER2-overexpressing human breast tumors (BT-474). The Journal of nutritional biochemistry. vol 26. issue 1. 2015-09-04. PMID:25441844. |
tumors treated with fso alone showed no difference in tumor growth compared to control; however, compared to tras2.5 and other groups, fso+tras2.5 caused significantly lower tumor growth and cell proliferation and higher apoptosis and the greatest lowering of signaling biomarker expressions (mapk2, her2 mrna; pher2 protein). |
2015-09-04 |
2023-08-13 |
mouse |
| Julie K Mason, Minghua Fu, Jianmin Chen, Lilian U Thompso. Flaxseed oil enhances the effectiveness of trastuzumab in reducing the growth of HER2-overexpressing human breast tumors (BT-474). The Journal of nutritional biochemistry. vol 26. issue 1. 2015-09-04. PMID:25441844. |
fso×tras interactive effect may be modulated by their combined reductions of her2 signaling through the akt and mapk pathways leading to reduced cell proliferation and increased apoptosis. |
2015-09-04 |
2023-08-13 |
mouse |
| Shuang Dou, Xian-Zhu Yang, Meng-Hua Xiong, Chun-Yang Sun, Yan-Dan Yao, Yan-Hua Zhu, Jun Wan. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer. Advanced healthcare materials. vol 3. issue 11. 2015-07-07. PMID:24947820. |
therefore, scfv(her2)-np(si) plk1 exhibits improved cellular uptake, promoted plk1 silencing efficiency, and induced enhanced tumor cell apoptosis in her2(+) breast cancer cells, when compared with nontargeted np(si) plk1. |
2015-07-07 |
2023-08-13 |
Not clear |
| Diana P English, Stefania Bellone, Carlton L Schwab, Ileana Bortolomai, Elena Bonazzoli, Emiliano Cocco, Natalia Buza, Pei Hui, Salvatore Lopez, Elena Ratner, Dan-Arin Silasi, Masoud Azodi, Peter E Schwartz, Thomas J Rutherford, Alessandro D Santi. T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo. Cancer medicine. vol 3. issue 5. 2015-06-30. PMID:24890382. |
t-dm1 was considerably more effective than trastuzumab in inhibiting cell proliferation and in causing apoptosis (p = 0.004) of usc showing her2 overexpression. |
2015-06-30 |
2023-08-13 |
mouse |
| Weihua Liu, Jinmei Xu, Yilun Liu, Xiaoping Yu, Xi Tang, Zhi Wang, Xin L. Anthocyanins potentiate the activity of trastuzumab in human epidermal growth factor receptor 2-positive breast cancer cells in vitro and in vivo. Molecular medicine reports. vol 10. issue 4. 2015-05-22. PMID:25070704. |
the combination treatments induced apoptosis, inhibited cell growth and affected her2 and its downstream signaling pathway in mda‑mb‑453, bt474 and hcc1569 cells, and the effects were synergistic. |
2015-05-22 |
2023-08-13 |
human |
| Siao-Syun Guan, Jungshan Chang, Chun-Chia Cheng, Tsai-Yueh Luo, Ai-Sheng Ho, Chia-Chi Wang, Cheng-Tien Wu, Shing-Hwa Li. Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo. Oncotarget. vol 5. issue 13. 2015-05-12. PMID:24947902. |
afatinib also inhibited the her2-positive tumor cell growth and caused apoptosis in her2-overexpressed human colorectal cancer hct-15 cells but not in low her2 expressed human gastric cancer mkn45 cells. |
2015-05-12 |
2023-08-13 |
human |
| Simon Brack, Isabella Attinger-Toller, Babette Schade, Frédéric Mourlane, Kristina Klupsch, Richard Woods, Helen Hachemi, Ulrike von der Bey, Susann Koenig-Friedrich, Julian Bertschinger, Dragan Grabulovsk. A bispecific HER2-targeting FynomAb with superior antitumor activity and novel mode of action. Molecular cancer therapeutics. vol 13. issue 8. 2015-05-11. PMID:24994770. |
one bispecific fynomab, cova208, was characterized in detail and showed a remarkable ability to induce rapid her2 internalization and apoptosis in vitro. |
2015-05-11 |
2023-08-13 |
Not clear |
| b' E D Bazhanova, V N Anisimov, D S Sukhanov, D L Teply\\xc4\\xa. [Comparative experimental study of the influence of drugs that improve brain metabolism (angiogen, cytoflavin) on neuronal apoptosis and function of cerebral cortex during aging]. Eksperimental\'naia i klinicheskaia farmakologiia. vol 78. issue 2. 2015-05-05. PMID:25898540.' |
in addition, results of our study showed morphological differences: increase in the apoptosis level of cortical neurons in aged fbv type mice, but no changes in aged her2 mice. |
2015-05-05 |
2023-08-13 |
mouse |
| Wei Huang, Qun-Dan Wu, Min Zhang, Ying-Li Kong, Pin-Rong Cao, Wei Zheng, Jian-Hua Xu, Min Y. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib. Cancer letters. vol 356. issue 2 Pt B. 2015-03-03. PMID:25449780. |
we found that fw-04-806 alone or with laptinib inhibits cell proliferation, induces cell apoptosis and reduces the total and activated her3 levels in these cells, while lapatinib has been reported to increase her3 expression followed her2 inhibition. |
2015-03-03 |
2023-08-13 |
human |
| Zhe Jiang, Jeff C Liu, Philip E D Chung, Sean E Egan, Eldad Zacksenhau. Targeting HER2(+) breast cancer: the TBK1/IKKε axis. Oncoscience. vol 1. issue 2. 2015-01-16. PMID:25594009. |
in addition, tbk1-ii cooperated with lapatinib, a egfr/her2 inhibitor, to accelerate apoptosis in vitro and suppress tumor growth in a xenograft model of her2(+) bc. |
2015-01-16 |
2023-08-13 |
mouse |
| Karin von Schwarzenberg, Tamás Lajtos, Làszló Simon, Rolf Müller, György Vereb, Angelika M Vollma. V-ATPase inhibition overcomes trastuzumab resistance in breast cancer. Molecular oncology. vol 8. issue 1. 2014-09-19. PMID:24055142. |
v-atpase inhibition with archazolid, a novel inhibitor of myxobacterial origin, results in growth inhibition, apoptosis and impaired her2 pro-survival signaling of the trastuzumab-resistant cell line jimt-1. |
2014-09-19 |
2023-08-12 |
mouse |
| Karin von Schwarzenberg, Tamás Lajtos, Làszló Simon, Rolf Müller, György Vereb, Angelika M Vollma. V-ATPase inhibition overcomes trastuzumab resistance in breast cancer. Molecular oncology. vol 8. issue 1. 2014-09-19. PMID:24055142. |
these results suggest that v-atpase inhibition by archazolid induces apoptosis and inhibits growth of trastuzumab-resistant tumor cells by retaining her2 in dysfunctional vesicles of the recycling pathway and consequently abrogates her2-signaling in vitro as well as in vivo. |
2014-09-19 |
2023-08-12 |
mouse |
| b' Suvi-Katri Leivonen, Kristine Kleivi Sahlberg, Rami M\\xc3\\xa4kel\\xc3\\xa4, Eldri Undlien Due, Olli Kallioniemi, Anne-Lise B\\xc3\\xb8rresen-Dale, Merja Per\\xc3\\xa4l\\xc3\\xa. High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. Molecular oncology. vol 8. issue 1. 2014-09-19. PMID:24148764.' |
the levels of her2, phospho-akt, phospho-erk1/2, cell proliferation (ki67) and apoptosis (cparp) were analyzed with reverse-phase protein arrays. |
2014-09-19 |
2023-08-12 |
human |
| Richard L Carpenter, Woody Han, Ivy Paw, Hui-Wen L. HER2 phosphorylates and destabilizes pro-apoptotic PUMA, leading to antagonized apoptosis in cancer cells. PloS one. vol 8. issue 11. 2014-09-02. PMID:24236056. |
her2 phosphorylates and destabilizes pro-apoptotic puma, leading to antagonized apoptosis in cancer cells. |
2014-09-02 |
2023-08-12 |
Not clear |
| Richard L Carpenter, Woody Han, Ivy Paw, Hui-Wen L. HER2 phosphorylates and destabilizes pro-apoptotic PUMA, leading to antagonized apoptosis in cancer cells. PloS one. vol 8. issue 11. 2014-09-02. PMID:24236056. |
her2 overexpression is known to reduce apoptosis but the underlying mechanisms for this association remain unclear. |
2014-09-02 |
2023-08-12 |
Not clear |